Export of medical cannabis
The Danish Medicines Agency is granting authorization to companies for the export of medical cannabis following the introduction of new legislation.
According to legislation introduced in January 2019, companies may be granted authorization for the export of cannabis products. Including primary products, intermediate products and bulk cannabis. However, such authorization is made conditional upon the company having previously obtained permission by the Danish Medicines Agency (Lægemiddelstyrelsen) to produce cannabis products.
The newly introduced legislation allows companies with the possibility to export, amongst others, cannabis primary products. Such export is limited to only those countries, which permit the import of cannabis for medicinal use. Further, while companies may be granted authorization for the export of certain cannabis primary products, such products must not have any affiliation – either through name or admission - to the list of cannabis primary products, which is produced by the Danish Medicines Agency.
In addition to cannabis primary products, authorization may now also be granted with regard to intermediate products. Companies that produce, and wish to export, intermediate products are under an obligation to ensure that their products are solely exported and delivered to companies, which have complied with the import country’s laws regarding cannabis intended for medicinal use. Additionally, for those companies who manufacture intermediate products, there is a further obligation imposed for the tracking of exported products and monitoring of potential defects. This obligation is especially important, considering the requirement stipulated by the new legislation that those companies granted the right to export medicinal cannabis must provide the relevant authority of the import country with overviews of all product errors, which may result in recalls.
Export of bulk cannabis
Finally, as with both cannabis primary products and intermediate products, authorization for the export of bulk cannabis may now also be granted to companies. Such companies are required to have previously obtained permission to grow and produce bulk cannabis.
Just as for those companies wishing to export intermediate products, companies exporting bulk cannabis are subject to the obligation to ensure that their products are solely exported and delivered to companies, which have complied with the import country’s laws regarding cannabis intended for medicinal use. Additionally, the further obligation imposed for the tracking of the exported products and monitoring of potential defects is applicable to exporters of bulk cannabis.
How can we help?
NJORD’s cannabis lawyers have already assisted several clients in successfully starting their operations under the pilot programme. We help throughout the entire process, from establishing your business and obtaining licenses to developing products and procedures. Contact our team of cannabis lawyers Partner Jeppe Brogaard Clausen and Assistant Attorney Heikki Selin.
Read more about medical cannabis: